Whitehawk Therapeutics(WHWK)

Focus: Whitehawk Therapeutics is a public biotechnology company focused on antibody-drug conjugate (ADC) therapies for oncology. The company is early-stage with minimal revenue and a concentrated pipeline of two Phase 1 programs.

Oncology

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Whitehawk Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Whitehawk Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$26M

FY2025

Pipeline & Clinical Trials

HWK-007

Endometrial Cancer

Phase 1

Clinical Trials (1)

NCT07444814Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Phase 1

Help build intelligence for Whitehawk Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on cutting-edge ADC modality with deep expertise in a high-value oncology segment
Public company status provides liquidity and potential equity upside as pipeline progresses to clinical data
Early-stage programs offer hands-on impact on drug development strategy and clinical execution

Watch Out For

Severe cash burn ($63.7M net loss in FY2025) against only $29M cash on hand creates existential runway concerns—likely 4-6 months of operations remaining
Zero active job openings and minimal publication output suggest reduced hiring and visibility; two Phase 1 programs represent pre-de-risking stage with high failure probability
Revenue of only $26M against $51M R&D spend indicates company is pre-commercial with no marketed products to stabilize balance sheet

Generated by Claude from Whitehawk Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

HWK-016, MUCIN-16-targeted ADC

PROC

Phase 1

Clinical Trials (1)

NCT07470853A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2006

Portfolio: 2 clinical trials

Top TAs: Oncology

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$26M86%

R&D Spend

$51M(196%)4%

Net Income

-$64M

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo